Re-challenging immune checkpoint inhibitor in a patient with advanced non-small cell lung cancer: a case report.

This case might suggest that re-challenging an ICP inhibitor could be clinically active in selected patients with advanced NSCLC who progress after achieving an initial clinical benefit with an ICP inhibitor.